Drug combination delivered by nanoparticles may help in melanoma treatment

HERSHEY, Pa. — The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers.

New driver, target in advanced mucosal melanoma

Not all melanomas are created equal. While most melanomas appear on the skin as the result of sun exposure, a small subset of melanomas arise spontaneously from mucosal tissues. And while targeted treatments and immunotherapies have dramatically improved the prognosis for many patients with sun-associated melanomas, these treatments are ineffective in the mucosal form of […]

Melanoma Takes Advantage of Missing Tumor-Suppressors to Resist Immunotherapy

Missing tumor-suppressing genes are the culprit behind resistance to immune checkpoint blockade drugs, investigators recently found.

Array BioPharma And Columbus’s Egg

In my first articles as a Seeking Alpha contributor, I’ve highlighted the potential of three widely differing companies: Bristol-Myers Squibb (NYSE:BMY), Tracon (NASDAQ:TCON) and Innate Pharma (OTCPK:IPHYF).

Cancer in the News

Feature Articles

COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Rare Cardiotoxicity Effects Founds With Checkpoint Inhibitors in Melanoma

As the oncology community adapts to using immunotherapy agents more frequently in cancer treatments, the fear over immune-related adverse events (irAEs) prevents many clinicians from fully trusting immunotherapies.

Read the full story

Posted in Melanoma In The News

Mutations in ATR Gene Promote Melanoma Tumor Growth

Investigators identified a mechanism used by melanoma cells to modulate the immune microenvironment to promote continued growth, according to a study.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

New Targets Explored to Boost Immunotherapy in Melanoma

While PD-1, PD-L1, and CTLA-4 checkpoint inhibitors have proven to be effective in treating patients with melanoma, not all patients respond to immunotherapy.

Read the full story

Posted in Melanoma In The News, Other Melanoma Research

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories